Publication: The future of il-1 targeting in kidney disease
Program
KU-Authors
KU Authors
Co-Authors
Afsar, Baris
Covic, Adrian
Ortiz, Alberto
Afsar, Rengin Elsurer
Publication Date
Language
Type
Embargo Status
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
Interleukin (IL)-1α and IL-1β are proinflammatory cytokines that play a role in many diseases such as rheumatoid arthritis, juvenile rheumatoid arthritis, gout, and periodic inflammatory syndromes, including familial Mediterranean fever and Muckle-Wells syndrome. Drugs targeting IL-1 such as recombinant IL-1Ra (anakinra), neutralizing anti-IL-1β antibodies (canakinumab) and IL-1β traps (rilonacept) are in clinical use to treat these diseases. Additionally, experimental evidence suggests a role of IL-1 in kidney disease and hypertension and targeting IL-1 showed promising results in high cardiovascular risk patients, hemodialysis and renal transplantation patients. We now summarize knowledge on the potential role of IL-1 targeting in patients with kidney disease.
Source
Publisher
Adis Int Ltd
Subject
Pharmacology, Pharmacy, Toxicology
Citation
Has Part
Source
Drugs
Book Series Title
Edition
DOI
10.1007/s40265-018-0942-2